Cutaneous Leishmaniasis. Cutaneous leishmaniasis
Conditions
Interventions
Intervention 1: Intervention group: reception of oral Clarithromycin with 500 mg dosage twice a day for two months. Intervention 2: Control group: treatment with systemic glucantime with 20 mg/kg dosa
Sponsors
Mashhad University of Medical Sciences
Eligibility
Sex/Gender
All
Age
16 Years to No maximum
Inclusion criteria
Inclusion criteria: having an indication of systemic treatment in patients with acute cutaneous leishmaniasis less than 12 weeks of illness receiving no previous treatment
Exclusion criteria
Exclusion criteria: Pregnancy Breastfeeding Use of other methods of treatment during the course of treatment Past medical history of any local or systemic disease during the last 2 months History of intolerance or allergies to macrolides A significant underlying disease such as heart, renal, or liver diseases. Use of other treatments before referral
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Percentage of complete recovery of the lesion. Timepoint: Follow-up and assessment of recovery are done every two weeks, and the duration of the therapeutic effect of the lesions is assessed based on changes in the size, extent, redness and firmness of the lesions. The treatment period is considered two month. Patients will also be followed 6 weeks, 3 months and 6 months after the treatment is over. Method of measurement: Measuring size of the lesion with digital caliper. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactSomaye Ghanizadeh
Mashhad University of Medical Sciences
Outcome results
None listed